fda glp-1 news november 2025 shortages weight loss drug Weight-Loss Drugs Could Address a Range of Addictions GLP-1 Trends: Access & Shortages, – takes aim at telehealth – FDA Decisions Expected: October 2025

What Happens Next The GLP1 Bridge is temporary and intended to inform CMSs future policy decisions

As a busy mom of four young children Semaglutide has helped me accomplish my health and wellness goals and I have lost 50 pounds

Inicio de medicamentos para el control del peso aprobados por la FDA

Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment